| Literature DB >> 22389707 |
Ken G Victor1, Joshua M Rady, Janet V Cross, Dennis J Templeton.
Abstract
Signal transduction pathways that are modulated by thiol oxidation events are beginning to be uncovered, but these discoveries are limited by the availability of relatively few analytical methods to examine protein oxidation compared to other signaling events such as protein phosphorylation. We report here the coupling of PROP, a method to purify reversibly oxidized proteins, with the proteomic identification of the purified mixture using mass spectrometry. A gene ontology (GO), KEGG enrichment and Wikipathways analysis of the identified proteins indicated a significant enrichment in proteins associated with both translation and mRNA splicing. This methodology also enabled the identification of some of the specific cysteine residue targets within identified proteins that are reversibly oxidized by hydrogen peroxide treatment of intact cells. From these identifications, we determined a potential consensus sequence motif associated with oxidized cysteine residues. Furthermore, because we identified proteins and specific sites of oxidation from both abundant proteins and from far less abundant signaling proteins (e.g. hepatoma derived growth factor, prostaglandin E synthase 3), the results suggest that the PROP procedure was efficient. Thus, this PROP-proteomics methodology offers a sensitive means to identify biologically relevant redox signaling events that occur within intact cells.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22389707 PMCID: PMC3289665 DOI: 10.1371/journal.pone.0032527
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1PROP-proteomics procedure.
Schematic diagram showing steps involved in the PROP-proteomics procedure that are described in detail in both Methods and Results.
Selected proteins identified using the PROP analysis on six replicate cell cultures treated or not with H2O2 that were preferentially identified after H2O2 oxidation treatment of cells.
| Protein | H2O2
| Untreated | ||||||||||||
| gi | Description | pValue | 1 | 2 | 3 | 4 | 5 | 6 | 1 | 2 | 3 | 4 | 5 | 6 |
| 50592994 | thioredoxin | 3.89E−046 | 4 (35) | 5 (46) | 5 (30) | 5 (31) | 4 (23) | 4 (23) | 1 (2) | 2 (4) | 2 (5) | 1 (1) | 1 (2) | 1 (1) |
| 4503483 | elongation factor 2 | 1.42E−102 | 6 (9) | 9 (13) | 4 (7) | 7 (13) | 8 (14) | 5 (9) | 1 (1) | 1 (1) | 1 (1) | X | X | 1 (1) |
| 4503481 | elongation factor 1-gamma | 9.40E−016 | 2 (2) | 1 (1) | 1 (1) | 1 (1) | 2 (2) | X | X | X | X | X | X | X |
| 15082258 | chromobox protein homolog 3 | 0.00E+000 | 2 (2) | 3 (5) | 1 (1) | 2 (3) | 1 (1) | 2 (3) | X | X | X | X | X | X |
| 4503545 | eukaryotic translation initiation factor 5A-1 iso B | 0.00E+000 | 8 (28) | 8 (23) | 12 (26) | 10 (21) | 8 (27) | 10 (24) | X | X | X | X | X | X |
| 4758516 | hepatoma-derived growth factor isoform a | 0.00E+000 | 8 (15) | 9 (16) | 7 (17) | 6 (12) | 6 (14) | 8 (11) | X | X | X | X | X | X |
| 10835063 | nucleophosmin isoform 1 | 0.00E+000 | 10 (43) | 9 (43) | 9 (40) | 10 (31) | 9 (35) | 9 (36) | X | X | X | X | X | X |
| 23308579 | prostaglandin E synthase 3 | 9.68E−023 | 2 (2) | 2 (2) | 2 (3) | 1 (2) | X | 1 (1) | X | X | X | X | X | X |
| 5031635 | cofilin-1 | 1.75E−134 | 9 (16) | 7 (11) | 6 (9) | 8 (12) | 8 (16) | 6 (13) | X | X | X | X | X | X |
| 10863927 | peptidyl-prolyl cis-trans isomerase A | 3.39E−087 | 6 (18) | 8 (23) | 8 (16) | 7 (21) | 6 (20) | 8 (27) | X | 1 (1) | X | X | X | X |
| 4504425 | high mobility group protein B1 | 4.40E−058 | 4 (5) | 5 (8) | 4 (5) | 3 (6) | 3 (4) | 2 (3) | X | X | X | X | X | X |
| 4506901 | serine/arginine-rich splicing factor 3 | 9.06E−047 | 3 (4) | 5 (6) | 4 (6) | 4 (7) | 4 (8) | 4 (5) | X | X | X | X | X | X |
| 17986258 | myosin light polypeptide 6 isoform 1 | 9.95E−039 | 3 (14) | 4 (13) | 3 (9) | 3 (13) | 3 (12) | 3 (10) | X | X | X | X | X | X |
| 4505303 | myosin light chain 6B | 2.40E−016 | 2 (2) | 2 (4) | 1 (1) | 2 (4) | 2 (4) | 2 (4) | X | X | X | X | X | X |
| 4557777 | myosin light chain 3 | 1.40E−013 | 1 (1) | 1 (2) | X | 1 (1) | 1 (1) | 1 (2) | X | X | X | X | X | X |
| 222352151 | poly(rC)-binding protein 1 | 1.98E−036 | 1 (1) | 2 (2) | 1 (1) | 1 (1) | 4 (5) | 1 (1) | X | X | X | X | X | X |
| 23308577 | D-3-phosphoglycerate dehydrogenase | 2.82E−025 | X | 2 (2) | 2 (3) | 1 (1) | 2 (2) | 1 (1) | X | X | X | X | X | X |
| 4505409 | nucleoside diphosphate kinase B isoform a | 1.62E−016 | 1 (1) | 1 (2) | 2 (2) | 2 (3) | 1 (1) | 1 (2) | X | X | X | X | X | X |
| 4504981 | galectin-1 | 5.82E−019 | 3 (7) | 4 (7) | 3 (7) | 2 (5) | 3 (4) | 3 (8) | X | X | X | X | X | X |
| 50053795 | eukaryotic translation initiation factor 4B | 2.84E−018 | 1 (1) | 1 (2) | 1 (3) | 1 (2) | 1 (2) | 1 (1) | X | X | X | X | X | X |
| 154355000 | far upstream element-binding protein 2 | 4.85E−014 | 3 (4) | 2 (3) | 2 (3) | 1 (2) | 3 (3) | 2 (3) | X | X | X | X | X | X |
| 72534660 | serine/arginine-rich splicing factor 7 isoform 1 | 5.18E−011 | 1 (1) | 2 (2) | 1 (1) | 2 (2) | 2 (2) | X | X | X | X | X | X | X |
| 14277700 | 40S ribosomal protein S12 | 1.29E−010 | 1 (2) | 1 (1) | 1 (2) | 1 (1) | X | 1 (1) | X | X | X | X | X | X |
| 4757714 | phosphotyrosine protein phosphatase isoform c | 5.75E−010 | 1 (1) | 1 (3) | X | 1 (1) | 1 (1) | 1 (2) | X | X | X | X | X | X |
| 4759098 | transformer-2 protein homolog beta | 2.51E−008 | 1 (2) | 2 (5) | 1 (1) | 2 (4) | X | X | X | X | X | X | X | X |
Leading number indicates the number of unique peptides for a particular protein that were observed while the number in parentheses indicates the total number of scans that were observed for that protein; in other words, a protein indicated as 3(13) had three unique peptides identified a total of 13 times. All of the scans tabulated passed a 3% FDR filter cutoff. An “X” indicates that no scans were observed that passed the FDR filter. The replicate analysis of 6 independent biological samples for both the control and H2O2 treated cells are shown. Data referred to in the text combine the replicate analyses.
The pValue represents the product of the best (i.e. smallest) eValue score observed for each unique peptide sequence for the given protein. This provides a relative measure of the overall confidence that the protein was in the sample (i.e. a true positive), with 0.00E+000 representing the highest confidence.
Selected proteins identified using the PROP analysis that were preferentially identified before H2O2 oxidation treatment of cells.
| Protein | H2O2
| Untreated | ||||||||||||
| gi | Description | pValue | 1 | 2 | 3 | 4 | 5 | 6 | 1 | 2 | 3 | 4 | 5 | 6 |
| 48255889 | glucosidase 2 subunit beta isoform 1 | 5.55E−119 | 9 (17) | 9 (18) | 7 (12) | 8 (18) | 8 (19) | 8 (19) | 13 (29) | 12 (27) | 13 (29) | 11 (25) | 13 (29) | 11 (23) |
| 42794771 | thioredoxin domain-containing protein 5 iso1 | 1.73E−049 | 2 (3) | 3 (3) | 1 (1) | 2 (2) | 1 (1) | 1 (1) | 5 (7) | 7 (8) | 6 (7) | 6 (8) | 6 (8) | 5 (7) |
| 10835143 | complement decay-accelerating factor isofo1 | 6.62E−045 | 1 (1) | 2 (3) | 1 (1) | 1 (1) | 2 (2) | 1 (1) | 6 (11) | 6 (8) | 6 (9) | 4 (9) | 3 (5) | 4 (7) |
| 4505591 | peroxiredoxin-1 | 2.81E−018 | 1 (1) | 1 (1) | X | 1 (1) | 1 (1) | X | 1 (1) | 2 (2) | 2 (2) | 1 (1) | 1 (2) | 2 (2) |
| 5453549 | peroxiredoxin-4 | 1.20E−007 | 2 (2) | X | 1 (1) | 1 (1) | X | X | 1 (2) | 2 (3) | 2 (2) | 2 (3) | 1 (1) | 2 (2) |
| 4758638 | peroxiredoxin-6 | 0.00E+000 | X | X | X | X | 1 (1) | X | 2 (2) | 3 (4) | 2 (2) | 2 (2) | 2 (3) | 1 (1) |
| 10835165 | CD59 glycoprotein preproprotein | 1.45E−018 | 1 (1) | 1 (1) | X | 1 (1) | X | X | 3 (3) | X | 1 (1) | 2 (2) | X | X |
| 10716563 | calnexin precursor | 0.00E+000 | X | X | X | X | 1 (1) | X | 3 (4) | 2 (2) | 2 (3) | 2 (2) | 3 (3) | 2 (2) |
| 38202257 | neutral alpha-glucosidase AB isoform 2 | 0.00E+000 | X | X | X | X | X | 1 (1) | 4 (5) | 3 (3) | 1 (1) | 2 (2) | 2 (2) | 1 (1) |
| 304376266 | putative serine protease 56 | 0.00E+000 | X | X | X | X | X | X | 4 (5) | 4 (4) | 5 (7) | 5 (9) | 3 (3) | 7 (8) |
| 38372919 | basigin isoform 1 precursor | 3.47E−036 | 1 (1) | X | X | X | X | X | 3 (4) | 3 (4) | 2 (3) | 2 (3) | 2 (2) | 3 (4) |
| 4758412 | polypeptide N-acetylgalactosaminyltransferase 2 | 1.16E−021 | X | X | X | X | X | X | 2 (2) | X | 1 (1) | 1 (1) | 2 (2) | 2 (3) |
| 40317626 | thrombospondin-1 precursor | 2.07E−021 | X | X | X | X | X | X | X | 2 (2) | X | 1 (1) | 1 (1) | 1 (1) |
| 24797067 | HLA class I histocompatibility antigen, A-1 alpha | 2.82E−007 | 1 (1) | X | X | X | X | X | 1 (1) | 1 (1) | 1 (2) | 1 (2) | 1 (1) | 1 (2) |
| 17986001 | major histocompatibility complex, class I, B precur | 1.54E−006 | X | X | X | X | X | X | 1 (2) | 1 (2) | 1 (2) | 1 (1) | 1 (2) | 1 (1) |
| 29725609 | epidermal growth factor receptor isoform a precur | 5.25E−006 | X | X | X | X | X | X | 1 (1) | 1 (2) | 1 (1) | 1 (1) | X | 1 (2) |
| 31542331 | protein CYR61 precursor | 2.10E−017 | X | X | X | X | X | X | 1 (1) | 1 (2) | 1 (1) | 1 (2) | 1 (1) | 2 (3) |
| 116734717 | alkaline phosphatase tissue-nonspec isozyme iso1 | 2.58E−012 | X | X | X | X | X | X | 1 (1) | 1 (1) | X | X | X | 1 (1) |
| 4503143 | cathepsin D preproprotein | 1.04E−024 | X | 1 (1) | 1(1) | X | 1 (1) | X | 1 (1) | 3 (3) | 2 (3) | 1 (1) | X | X |
| 22538442 | cathepsin Z preproprotein | 3.78E−014 | X | X | X | X | X | X | X | X | X | 1 (1) | 1 (1) | X |
| 5031863 | galectin-3-binding protein | 5.66E−004 | X | X | X | X | X | X | X | X | X | X | 1 (1) | X |
| 17149842 | peptidyl-prolyl cis-trans isomerase FKBP2 precur | 2.48E−022 | X | X | X | X | X | 1 (1) | 2 (2) | 1 (1) | 1 (1) | X | 1 (1) | 1 (1) |
| 167614504 | laminin subunit beta-1 precursor | 1.29E−016 | X | X | X | X | X | X | X | 2 (2) | 1 (1) | X | X | 1 (1) |
| 54607120 | lactotransferrin isoform 1 precursor | 9.38E−011 | X | X | X | X | X | 1 (1) | 1 (1) | 2 (2) | 1 (1) | 2 (2) | 1 (1) | 1 (1) |
Leading number indicates the number of unique peptides for a particular protein that were observed while the number in parentheses indicates the total number of scans that were observed for that protein. All of the scans tabulated passed a 3% FDR filter cutoff. An “X” indicates that no scans were observed that passed the FDR filter. The replicate analysis of 6 independent biological samples for both the control and H2O2 treated cells are shown. Data referred to in the text combine the replicate analyses.
The pValue represents the product of the best (i.e. smallest) eValue score observed for each unique peptide sequence for the given protein. This provides a relative measure of the overall confidence that the protein was in the sample (i.e. a true positive), with 0.00E+000 representing the highest confidence.
Selected peptides that were observed with a cysteine residue that had been biologically oxidized from proteins that were preferentially identified after H2O2 oxidation treatment of cells.
| Protein | Peptide | H2O2
| Untreated | ||||||||||||
| gi | Description | Sequence | eValue | 1 | 2 | 3 | 4 | 5 | 6 | 1 | 2 | 3 | 4 | 5 | 6 |
| 4503545 | eukaryotic translation initiation factor 5A-1 iso B |
| 4.57E−014 | 3 | 0 | 2 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4503545 | eukaryotic translation initiation factor 5A-1 iso B |
| 2.28E−015 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4503545 | eukaryotic translation initiation factor 5A-1 iso B |
| 4.35E−018 | 2 | 2 | 2 | 2 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4503545 | eukaryotic translation initiation factor 5A-1 iso B |
| 2.40E−012 | 1 | 1 | 1 | 2 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4504981 | galectin-1 |
| 3.08E−008 | 1 | 1 | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4758516 | hepatoma-derived growth factor isoform a |
| 3.72E−003 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5031635 | cofilin-1 |
| 1.76E−019 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5031635 | cofilin-1 |
| 1.15E−009 | 2 | 2 | 0 | 2 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| 10863927 | peptidyl-prolyl cis-trans isomerase A |
| 6.62E−015 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 10863927 | peptidyl-prolyl cis-trans isomerase A |
| 1.97E−008 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 14277700 | 40S ribosomal protein S12 |
| 1.29E−010 | 2 | 1 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 15082258 | chromobox protein homolog 3 |
| 7.03E−009 | 0 | 1 | 1 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| 20149594 | heat shock protein HSP 90-beta |
| 1.18E−012 | 1 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 23308579 | prostaglandin E synthase 3 |
| 3.13E−014 | 1 | 1 | 2 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 50592994 | thioredoxin |
| 6.07E−005 | 2 | 1 | 1 | 2 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| 50592994 | thioredoxin |
| 2.38E−018 | 15 | 17 | 11 | 5 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| 148298677 | hydroxymethylglutaryl-CoA synthase, cytoplasmic |
| 1.04E−007 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 148298677 | hydroxymethylglutaryl-CoA synthase, cytoplasmic |
| 3.63E−007 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 222352151 | poly(rC)-binding protein 1 |
| 7.38E−006 | 1 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The total number of scans that were observed for that peptide. All of the scans tabulated passed a 3% FDR filter cutoff. The replicate analysis of 6 independent biological samples for both the control and H2O2 treated cells are shown. Data referred to in the text combine the replicate analyses.
The eValue represents the best (i.e. smallest) OMSSA eValue score matched to the particular peptide sequence. This provides a relative measure of the overall confidence that the peptide was in the sample (i.e. a true positive), with 0.00E+000 representing the highest confidence.
Lower case “c” indicates location of carboxyamidomethyl derivatization(s).
Selected peptides that were observed with a cysteine residue that had been biologically oxidized from proteins that were preferentially identified before H2O2 oxidation treatment of cells.
| Protein | Peptide | H2O2
| Untreated | ||||||||||||
| gi | Description | Sequence | eValue | 1 | 2 | 3 | 4 | 5 | 6 | 1 | 2 | 3 | 4 | 5 | 6 |
| 10716563 | calnexin precursor |
| 3.91E−298 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 1 | 1 | 1 |
| 4505591 | peroxiredoxin-1 |
| 1.61E−012 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 1 |
| 4758638 | peroxiredoxin-6 |
| 2.58E−008 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| 10835143 | complement decay-accelerating factor iso1 |
| 8.81E−011 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 2 | 0 | 1 |
| 10835143 | complement decay-accelerating factor iso1 |
| 7.05E−011 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| 10835143 | complement decay-accelerating factor iso1 |
| 2.65E−006 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 0 | 0 | 1 |
| 10835143 | complement decay-accelerating factor iso1 |
| 1.74E−007 | 0 | 2 | 0 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 1 |
| 10835143 | complement decay-accelerating factor iso1 |
| 1.58E−003 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 |
| 304376266 | putative serine protease 56 |
| 3.78E−012 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 304376266 | putative serine protease 56 |
| 5.96E−007 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 1 | 1 |
| 304376266 | putative serine protease 56 |
| 1.99E−004 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 1 | 1 |
| 10835165 | CD59 glycoprotein preproprotein |
| 2.75E−009 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| 10835165 | CD59 glycoprotein preproprotein |
| 2.44E−005 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| 31542331 | protein CYR61 precursor |
| 8.87E−009 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 31542331 | protein CYR61 precursor |
| 2.37E−009 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 2 | 1 | 2 |
| 38372919 | basigin isoform 1 precursor |
| 4.90E−015 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 2 |
| 17149842 | peptidyl-prolyl cis-trans isomerase FKBP2 precur |
| 3.85E−014 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 |
| 29725609 | epidermal growth factor receptor isoform a precur |
| 5.25E−006 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 1 | 0 | 2 |
| 42794771 | thioredoxin domain-containing protein5 iso1 precur |
| 4.39E−016 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 |
| 42794771 | thioredoxin domain-containing protei 5 iso1 precur |
| 3.09E−004 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 1 |
| 40317626 | thrombospondin-1 precursor |
| 6.22E−009 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 48255889 | glucosidase 2 subunit beta isoform 1 |
| 1.92E−008 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| 48255889 | glucosidase 2 subunit beta isoform 1 |
| 1.26E−009 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 2 | 1 | 1 | 1 |
| 54607120 | lactotransferrin isoform 1 precursor |
| 6.65E−007 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| 167614504 | laminin subunit beta-1 precursor |
| 6.38E−005 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 |
The total number of scans that were observed for that peptide. All of the scans tabulated passed a 3% FDR filter cutoff. The replicate analysis of 6 independent biological samples for both the control and H2O2 treated cells are shown. Data referred to in the text combine the replicate analyses.
The eValue represents the best (i.e. smallest) OMSSA eValue score matched to the particular peptide sequence. This provides a relative measure of the overall confidence that the peptide was in the sample (i.e. a true positive), with 0.00E+000 representing the highest confidence.
Lower case “c” indicates location of carboxyamidomethyl derivatization(s).
Gene ontology (GO) analysis of proteins that were preferentially identified after H2O2 oxidation treatment of cells.
| GO Biological Process | Protein | ||||||
| Translation2.98E−05 | mRNA Processing4.11e−07 | Nuclear mRNA Splicing, via Spliceosome3.36e−08 | Entrez gene | gi | Mass [kDa] | Description | pValue |
| X | X | 6432 | 72534660 | 27.37 | serine/arginine-rich splicing factor 7 isoform 1 | 5.18E−011 | |
| X | X | 4869 | 10835063 | 32.57 | nucleophosmin isoform 1 | 0.00E+000 | |
| X | X | 6434 | 4759098 | 33.67 | transformer-2 protein homolog beta | 2.51E−008 | |
| X | X | 3191 | 52632383 | 64.13 | heterogeneous nuclear ribonucleoprotein L isoform a | 1.17E−009 | |
| X | X | 6428 | 4506901 | 19.33 | serine/arginine-rich splicing factor 3 | 9.06E−047 | |
| X | X | 5093 | 222352151 | 37.50 | poly(rC)-binding protein 1 | 1.98E−036 | |
| X | X | 220988 | 34740329 | 39.59 | heterogeneous nuclear ribonucleoprotein A3 | 2.26E−007 | |
| X | X | 8683 | 4506903 | 25.54 | serine/arginine-rich splicing factor 9 | 4.98E−004 | |
| X | X | 5094 | 14141166 | 38.22 | poly(rC)-binding protein 2 isoform b | 2.55E−013 | |
| X | X | 1207 | 4502891 | 26.22 | methylosome subunit pICln | 8.07E−012 | |
| X | X | 6426 | 5902076 | 27.74 | serine/arginine-rich splicing factor 1 isoform 1 | 1.15E−004 | |
| X | 4841 | 34932414 | 54.23 | non-POU domain-containing octamer-binding protein isoform 1 | 4.44E−006 | ||
| X | 8570 | 154355000 | 73.12 | far upstream element-binding protein 2 | 4.85E−014 | ||
| X | 1984 | 4503545 | 16.83 | eukaryotic translation initiation factor 5A-1 isoform B | 0.00E+000 | ||
| X | 3692 | 4504771 | 26.60 | eukaryotic translation initiation factor 6 isoform a | 4.05E−013 | ||
| X | 2617 | 1.17E+08 | 83.16 | glycyl-tRNA synthetase | 1.89E−018 | ||
| X | 1975 | 50053795 | 69.15 | eukaryotic translation initiation factor 4B | 2.84E−018 | ||
| X | 1938 | 4503483 | 95.34 | elongation factor 2 | 1.42E−102 | ||
| X | 23708 | 46094014 | 68.88 | eukaryotic peptide chain release factor GTP-binding subunit ERF3B | 1.19E−004 | ||
| X | 6176 | 4506669 | 11.51 | 60S acidic ribosomal protein P1 isoform 1 | 5.60E−010 | ||
| X | 6206 | 14277700 | 14.51 | 40S ribosomal protein S12 | 1.29E−010 | ||
| X | 1937 | 4503481 | 50.12 | elongation factor 1-gamma | 9.40E−016 | ||
| X | 3315 | 4504517 | 22.78 | heat shock protein beta-1 | 0.00E+000 | ||
| X | 136319 | 21956645 | 12.89 | myotrophin | 5.60E−018 | ||
| X | 1933 | 4503477 | 24.76 | elongation factor 1-beta | 6.79E−010 | ||
The adjusted pValue assigned to the biological process by the WebGestalt GO analysis using the hypergeometric statistical test with a BH multiple test adjustment.
Figure 2Potential Consensus Sequence for Oxidized Cysteine Residues.
The sequence logo representation of the frequency of the amino acid residues surrounding the oxidized cysteine residues, located at position “0”, that were identified from the PROP proteomics procedure.